Milestone Pharmaceuticals (NASDAQ:MIST) Receives Buy Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $25.00 target price on the stock.

Separately, Piper Sandler decreased their target price on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 5th.

Milestone Pharmaceuticals Price Performance

MIST stock traded up $0.01 during mid-day trading on Monday, reaching $1.33. 57,343 shares of the company traded hands, compared to its average volume of 258,100. The company has a fifty day moving average price of $1.57 and a 200-day moving average price of $1.69. Milestone Pharmaceuticals has a 52-week low of $1.22 and a 52-week high of $3.86. The company has a market capitalization of $70.84 million, a P/E ratio of -1.06 and a beta of 1.63. The company has a debt-to-equity ratio of 1.27, a current ratio of 22.75 and a quick ratio of 22.75.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. As a group, analysts anticipate that Milestone Pharmaceuticals will post -0.79 earnings per share for the current year.

Institutional Trading of Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. BML Capital Management LLC raised its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 442,352 shares of the company’s stock after buying an additional 169,852 shares during the quarter. Milestone Pharmaceuticals comprises 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd largest position. BML Capital Management LLC owned approximately 1.32% of Milestone Pharmaceuticals worth $739,000 as of its most recent SEC filing. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.